• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Peptic Ulcer Partnering 2009-2014 Product Image

Peptic Ulcer Partnering 2009-2014

  • Published: August 2014
  • Region: Global
  • 100 pages
  • CurrentPartnering

FEATURED COMPANIES

  • Abbott
  • Baxter International
  • Dainippon Sumitomo
  • Grifols
  • Mitsubishi Tanabe
  • Servier
  • MORE

The Peptic Ulcer Partnering 2009-2014 report provides understanding and access to the peptic ulcer partnering deals and agreements entered into by the worlds leading healthcare companies.

- Trends in peptic ulcer partnering deals
- Top peptic ulcer deals by value
- Deals listed by company A-Z, industry sector, stage of development, technology type

The Peptic Ulcer Partnering 2009-2014 provides understanding and access to the peptic ulcer partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of peptic ulcer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors peptic ulcer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, READ MORE >

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in peptic ulcer partnering

- 2.1. Introduction
- 2.2. Peptic ulcer partnering over the years
- 2.3. Bigpharma peptic ulcer dealmaking activity
- 2.4. Peptic ulcer partnering by deal type
- 2.5. Peptic ulcer partnering industry sector
- 2.6. Peptic ulcer partnering by stage of development
- 2.7. Peptic ulcer partnering by technology type
- 2.8. Disclosed financial deal terms for peptic ulcer partnering
- 2.8.1 Peptic ulcer headline values
- 2.8.2 Peptic ulcer upfront payments
- 2.8.3 Peptic ulcer milestone payments
- 2.8.4 Peptic ulcer royalty rates

Chapter 3 – Leading peptic ulcer deals

- 3.1. Introduction
- 3.2. Top peptic ulcer deals by value
- 3.3. Top peptic ulcer deals involving bigpharma

Chapter 4 – Dealmaking directory

- 4.1. Introduction
- 4.2. Company A-Z
- 4.3. By deal type
- Asset purchase
- Bigpharma outlicensing
- Co-development
- Collaborative R&D
- Co-market
- Contract service
- Co-promotion
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Settlement
- Spin out
- Sub-license
- Supply
- Termination
- 4.4. By industry sector
- Academic
- Bigpharma
- Biotech
- Drug delivery
- Medical device
- Diagnostic
- Generic pharma
- Government
- Non-profit
- Pharmaceutical
- Research tools
- Services
- Specialty pharma
- 4.5. By stage of development
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Registration
- Marketed
- 4.6. By technology type
- Analysis
- Animal models
- Assays
- Bioinformatics
- Biological compounds
- Biomarkers
- Biomaterials
- Cell culture
- Cell therapy
- Clinical testing
- Diagnostic - companion
- Devices
- Diagnostics
- Discovery tools
- DNA probes
- Drug delivery
- Enabling technology
- Epigenetics
- Equipment
- Facilities
- Gene therapy
- Genomics
- Imaging
- Industrial chemicals
- In vitro models
- Monoclonal antibodies
- Nanotechnology
- Oligonucleotide
- Peptides
- Personalised medicine
- Processes
- Proteomics
- Radio/Chemo-therapy
- Recombinant DNA
- Research services
- Research supplies
- RNA therapeutics
- Screening
- Small molecules
- Stem cells
- Vaccines

Chapter 5 – Partnering resource center

- 5.1. Online partnering
- 5.2. Partnering events
- 5.3. Further reading on dealmaking

Appendices

- Appendix 1 – Deal type definitions

About Wildwood Ventures

- Current Partnering
- Current Agreements
- Recent titles from CurrentPartnering
- Order Form – Reports

Table of figures

- Figure 1: peptic ulcer partnering since 2009
- Figure 2: Bigpharma – top 50 – peptic ulcer deals 2009 to 2011
- Figure 3: Bigpharma peptic ulcer deal frequency – 2009 to 2011
- Figure 4: Peptic ulcer partnering by deal type since 2009
- Figure 5: Peptic ulcer partnering by industry sector since 2009
- Figure 6: Peptic ulcer partnering by stage of development since 2009
- Figure 7: Peptic ulcer partnering by technology type since 2009
- Figure 8: Peptic ulcer deals with a headline value
- Figure 9: Peptic ulcer deals with upfront payment values
- Figure 10: Peptic ulcer deals with milestone payments
- Figure 11: Peptic ulcer deals with royalty rates, %
- Figure 12: Top peptic ulcer deals by value since 2009
- Figure 13: Top peptic ulcer deals signed by bigpharma value since 2009
- Figure 14: Online partnering resources
- Figure 15: Forthcoming partnering events
- Figure 16: Deal type definitions

Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
Valeant
Warner Chilcott
Watson

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos